Gilead plans to skip from Phase 1 to Phase 3 with once-yearly PrEP drug
Gilead said two experimental once-a-year versions of its HIV prevention shot lenacapavir passed muster in an early-stage study with a small group of healthy participants. The drugmaker is now planning to launch directly into a ...
Gilead said two experimental once-a-year versions of its HIV prevention shot lenacapavir passed muster in an early-stage study with a small group of healthy participants.
The drugmaker is now planning to launch directly into a ...
